Anti-inflammatory effects of topical erythromycin and clindamycin in acne patients

Phase 1

Active, not recruiting

• Conditions: Acne vulgaris; MedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders; Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

• Registration Number: EUCTR2017-003105-18-NL
• Lead Sponsor: Centre for Human Drug Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-12-06
• Last Update Posted: 29 June 2020

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1.Healthy male and female subjects, 18 to 45 years of age. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than AV following a detailed medical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis;
2.Mild to moderate inflammatory acne vulgaris on the face, =5 inflammatory lesions (papules and/or pustules), present at screening and baseline visit
3.A maximum of 5 nodules present at screening and baseline visit
4.Inflammatory acne present for at least 6 months
5.Fitzpatrick skin type I-II (Caucasian)
6.Able and willing to give written informed consent and to comply with the study restrictions.
7.Willing to comply with 2x2mm facial skin punch biopsies

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Severe acne where systemic treatment is needed
2.Use of any topical (anti-acne) medication (prescription or OTC) within 2 weeks prior to baseline
3.Use of any oral/systemic treatment for acne, including oral antibiotics, excluding OAC, within 4 weeks prior to baseline
4.Use of systemic isotretinoin within 6 months prior to baseline
5.History of pathological scar formation (keloid, hypertrophic scar)
6.Known hypersensitivity to erythromycin or clindamycin, drugs of the same class, or any of their excipients.
7.Known contact dermatitis reaction to any product
8.Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment.
9.Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.
10.Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening
11.Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified